Onconic Therapeutics Presents Preclinical Research Results of Targeted Anticancer Drug at AACR

Next-Generation Dual-Inhibitor Targeted Anticancer Drug Candidate 'Nesuparip'

Onconic Therapeutics announced on the 13th that it will present the preclinical results of its next-generation dual-inhibitor targeted anticancer drug candidate, Nesuparip, at the 'American Association for Cancer Research (AACR) 2025' conference to be held in April. AACR is known as one of the top three cancer research conferences worldwide.

Onconic Therapeutics

Nesuparip is a novel drug candidate with a dual mechanism that simultaneously inhibits PARP and Tankyrase.

It has currently received orphan drug designation for pancreatic cancer from the U.S. Food and Drug Administration (FDA) and is undergoing Phase 1b/2 clinical trials targeting first-line treatment for metastatic pancreatic cancer. Since last year, in collaboration with Severance Hospital, investigator-initiated Phase 2 clinical trials combining Nesuparip with Keytruda for endometrial cancer are also underway.

At this conference, Onconic Therapeutics plans to demonstrate the potential of Nesuparip as an innovative therapy by presenting research results in new indications beyond those of existing PARP inhibitors.

Hyunju Cha, Executive Director of Onconic Therapeutics, stated, "The preclinical study selected for poster presentation confirms the potential of a new therapeutic indication that existing PARP inhibitors have not yet entered, demonstrating the excellent efficacy of Nesuparip."

This content was produced with the assistance of AI translation services.